Table 1.
Monovalent and hepatitis A antigen containing HAV vaccines brands reported on in the publications reviewed (Tables 2–5)
| Trade name | HAV strain | Adjuvant | HAV antigen Dose/Volume (mL) per Injection | Manufacturer (Country) | |
|---|---|---|---|---|---|
| Pediatric |
Adult |
||||
| Inactivated vaccines | |||||
| Avaxim | GBM | Aluminum hydroxide | 80 U/0.5 | 160 U/0.5 | Sanofi Pasteur (France) |
| Epaxala | RG-SB | Virosomes | 12 IU/0.25 | 24 IU/0.5 | Crucell/Janssenb (Switzerland) |
| Havrix | HM-175 | Aluminum hydroxide | 720 EU/0.5 | 1440 EU/1.0 | GSK (Belgium) |
| Healive | TZ84 | Aluminum hydroxide | 250 U/0.5 | 500 U/1.0 | Sinovac Biotech (China) |
| Twinrix (+HBsAg) | HM-175 | Aluminum hydroxide | 360 EU/0.5 | 720 EU/1.0 | GSK (Belgium) |
| VAQTA | CR-326 | Aluminum hydroxide | 25 U/0.5 | 50 U/1.0 | MSD (USA) |
| Live-attenuated vaccines | |||||
| Biovac-A | H2 | None | 6.5log TCID50/0.5 mL | 6.5 log TCID50/1.0 mL | Zhejiang Pukang Biotech (China) |
| HAVAC | LA-1 | None | 6.5log TCID50/0.5 mL | 6.5 log TCID50/1.0 mL | Changchun Inst. of Biologic Products (China) |
Contents of this table adapted/taken from WHO (2019),3 Lemon et al. (2018),4 and Cui et al. (2014);20 aFor economic reasons not on the market anymore; bFormerly ‘Berna Biotech’ (Swiss Serum & Vaccine Institute)
Abbreviations: HAV: hepatitis A virus; IU: international units; EU: ELISA units; U: antigen units; HBsAg: hepatitis B virus surface antigen; TCID: tissue culture infecting dose